C-Path Leads Novel Transatlantic Drug Safety Effort
Companies receive go ahead from FDA and EMEA to use new improved tests when assessing safety of new drugs.
Related Posts
-
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) -
C-Path and CHDI launch consortium to accelerate development of Huntington’s disease therapies -
Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker -
C-Path and CDISC Announce Therapeutic Area User Guide for Duchenne Muscular Dystrophy -
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide